A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
|Articles|December 5, 2018
Managing Costs and Advancements in Biosimilars
https://www.pharmacytimes.org/on-demand/an-american-journal-of-managed-care-supplement-managing-costs-and-advancements-in-biosimilars
Advertisement
Advertisement
Related to this article
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.
Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5